![Anat Kerem-Angel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Career history of Anat Kerem-Angel
Former positions of Anat Kerem-Angel
Companies | Position | Start | End |
---|---|---|---|
Youdim Pharmaceuticals Ltd.
![]() Youdim Pharmaceuticals Ltd. Investment ManagersFinance Youdim Pharmaceuticals Ltd (Youdim Pharmaceuticals) is a venture capital subsidiary of XT Investments Ltd founded in 1997. The firm is headquartered in Yokneam, Israel. | Private Equity Investor | 31/12/2003 | 30/12/2010 |
Thrombotech Ltd.
![]() Thrombotech Ltd. Medical SpecialtiesHealth Technology Thrombotech Ltd. is an Israel-based biotechnological company that is based on years of cutting-edge thrombotic research at the Hadassah Medical Center in Jerusalem. Thrombotech developed a peptide called THR-18, which allows the existing thrombolytic stroke medication to easily dissolve blood clots, extending its short therapeutic time window and diminishing life-threatening side effects. The company was founded in 2000 and is headquartered in Rehovot, Israel. | Director/Board Member | - | - |
Training of Anat Kerem-Angel
Tel-Aviv University | Doctorate Degree |
Statistics
International
Israel | 4 |
Operational
Private Equity Investor | 1 |
Director/Board Member | 1 |
Doctorate Degree | 1 |
Sectoral
Finance | 2 |
Health Technology | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Youdim Pharmaceuticals Ltd.
![]() Youdim Pharmaceuticals Ltd. Investment ManagersFinance Youdim Pharmaceuticals Ltd (Youdim Pharmaceuticals) is a venture capital subsidiary of XT Investments Ltd founded in 1997. The firm is headquartered in Yokneam, Israel. | Finance |
Thrombotech Ltd.
![]() Thrombotech Ltd. Medical SpecialtiesHealth Technology Thrombotech Ltd. is an Israel-based biotechnological company that is based on years of cutting-edge thrombotic research at the Hadassah Medical Center in Jerusalem. Thrombotech developed a peptide called THR-18, which allows the existing thrombolytic stroke medication to easily dissolve blood clots, extending its short therapeutic time window and diminishing life-threatening side effects. The company was founded in 2000 and is headquartered in Rehovot, Israel. | Health Technology |
- Stock Market
- Insiders
- Anat Kerem-Angel
- Experience